« View all Healthcare Advisors

Daniel M. Skovronsky, MD, PhD — Avid Radiopharmaceuticals

Daniel M. Skovronsky is Founder, President and CEO of Avid Radiopharmaceuticals (a former Safeguard Partner Company), which was acquired by Eli Lilly in December 2010 for an upfront payment of $300 million, and the potential for an additional $500 million in additional payments contingent upon potential future regulatory and commercial milestones for Amyvid.

Dr. Skovronsky has more than 20 peer-reviewed publications and two NIH-funded grants on Alzheimer’s disease research. Prior to establishing Avid, Dr. Skovronsky served as Scientific Director of High Throughput Screening and Drug Discovery at the Center for Neurodegenerative Disease Research at the University of Pennsylvania. Dr. Skovronsky trained as a resident in Pathology and completed a fellowship in Neuropathology at the Hospital of the University of Pennsylvania.

Dr. Skovronsky received his M.D. and Ph.D. from the University of Pennsylvania and did his undergraduate training in molecular biochemistry at Yale University. Dr. Skovronsky is the recipient of numerous scientific and business awards and was recently named by the Philadelphia Business Journal as one of their “Forty under Forty” business leaders in the region. Dr. Skovronsky recently received the Ernst & Young Entrepreneur Of The Year^®; 2009 Award in the Emerging Company category in Greater Philadelphia, which recognizes outstanding entrepreneurs who are building and leading dynamic, growing businesses.